Deals this week: Kerecis, PharmaJet, Fimbrion Therapeutics

27th October 2016 (Last Updated October 27th, 2016 18:30)

Kerecis and the US Department of Defence have entered an agreement to develop fish skin burn treatment.

Kerecis and the US Department of Defence have entered an agreement to develop fish skin burn treatment.

As part of the agreement, Kerecis will modify and test its existing fish skin technology in curing the burn injuries through preclinical and clinical studies, while the US Army Medical Research and Material Command will be responsible for funding the research programme.

The agreement enables Kerecis to introduce new treatment for burn wounds.

PharmaJet and Vaccibody have entered a co-development agreement to develop a needle-free human papillomavirus (HPV) vaccine.

"PharmaJet and Vaccibody have entered a co-development agreement to develop a needle-free human papillomavirus (HPV) vaccine."

The two partners will jointly work on developing the needle-free injection to deliver the HPV vaccine.

Fimbrion Therapeutics and GlaxoSmithKline have entered an agreement to develop new antibacterial therapies for urinary tract infections (UTIs).

The two partners will work on a project focused on developing small molecule compounds for the treatment of UTIs.

The agreement enables the partners to treat and prevent UTIs using mannosides.

Pluristem Therapeutics plans to raise gross proceeds of $30m through the private placement of 16.8 million of its common stock shares.

The placement will be subscribed to by Innovative Medical Management.

Pluristem plans to invest the funds to further advance the late-stage trials for its cell therapies.

Everstone Capital Management has acquired a 70% stake in Rubicon Research for a purchase consideration of $33m.

The transaction allows Rubicon Research to further advance its growth strategy.